NREP
NEW REPRESENTATIVE AT IB RECEIVED
19/06/2025
Voltar para busca
Dado oficial do USPTO
ELATIVE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
29
Atualização mais recente
20/06/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
5, 42
Data de depósito
20/01/2021
Data de registro
29/03/2022
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
29/03/2022
Última transação
20/06/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
33
Localização do titular
FR
Examinador
HUDSON, TAMARA
Unidade examinadora
L40
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
GENFIT
Representantes
Brooks R. Bruneau FisherBroyles LLP
Classificação técnica
Classes Nice
Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 5
Pharmaceutical preparations for the prevention and treatment of liver diseases, cholestatic diseases, metabolic diseases, cancer diseases, inflammatory diseases, autoimmune diseases and cancers; chemical preparations for medical or pharmaceutical use, namely for the prevention and treatment of liver diseases, cholestatic diseases, metabolic diseases, cancer diseases, inflammatory diseases, autoimmune diseases and cancers; organic preparations for medical or pharmaceutical use, namely for the prevention and treatment of liver diseases, cholestatic diseases, metabolic diseases, cancer diseases, inflammatory diseases, autoimmune diseases and cancers; diagnostic preparations for medical use; diagnostic reagents for medical use
Classe 42
Scientific research for medical purposes; pharmaceutical research and development services; conducting clinical trials for pharmaceutical products for others, in particular conducting clinical trials for determining the efficacy and safety of elafibranor; conducting clinical trials for others to determine the efficacy and safety of pharmaceutical products in the treatment of primary biliary cholangitis (PBC); conducting scientific studies and analyses in the field of pharmaceuticals and medicines; scientific research and development, namely, providing information, results and data relating to scientific or medical research and development of pharmaceutical products, via an online searchable database; conducting clinical trials for others; pharmaceutical and biological product development and research services for third parties; conducting clinical research for others; evaluation of the efficacy of pharmaceutical products; clinical product development services
Publicações
Histórico de despachos e eventos da marca no USPTO.
29 publicações encontradas
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
12/09/2022
FICS
FINAL DISPOSITION NOTICE SENT TO IB
23/08/2022
FIMP
FINAL DISPOSITION PROCESSED
23/08/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
29/06/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
08/05/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
29/03/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
11/01/2022
PUBO
PUBLISHED FOR OPPOSITION
11/01/2022
GPNX
NOTIFICATION PROCESSED BY IB
10/01/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
22/12/2021
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
22/12/2021
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
22/12/2021
PREV
LAW OFFICE PUBLICATION REVIEW COMPLETED
09/12/2021
ALIE
ASSIGNED TO LIE
09/12/2021
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
08/12/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/12/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/12/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/12/2021
RFNT
REFUSAL PROCESSED BY IB
11/09/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
25/08/2021
RFRR
REFUSAL PROCESSED BY MPU
25/08/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/08/2021
CNRT
NON-FINAL ACTION WRITTEN
06/08/2021
DOCK
ASSIGNED TO EXAMINER
03/08/2021
MAFR
APPLICATION FILING RECEIPT MAILED
12/06/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
08/06/2021
LIMI
LIMITATION FROM ORIGINAL APPLICATION ENTERED
07/06/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
03/06/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace ELATIVE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.